Provided by Tiger Fintech (Singapore) Pte. Ltd.

89Bio, Inc.

8.08
-0.8800-9.82%
Post-market: 8.080.00000.00%18:28 EDT
Volume:1.92M
Turnover:15.64M
Market Cap:1.18B
PE:-2.30
High:8.94
Open:8.94
Low:7.90
Close:8.96
Loading ...

89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024

THOMSON REUTERS
·
15 Nov 2024

BUZZ-89bio slips after $125 mln stock deal

Reuters
·
13 Nov 2024

89bio Prices $125 Million Offering

MT Newswires Live
·
13 Nov 2024

89bio drops 2%, prices $125M stock offering

seekingalpha
·
13 Nov 2024

BRIEF-89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
13 Nov 2024

89Bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
13 Nov 2024

89Bio Inc - Prices Upsized Public Offering of 11.46 Mln Shares at $8.50 Each

THOMSON REUTERS
·
13 Nov 2024

89bio announces $100M common stock offering

TIPRANKS
·
13 Nov 2024

89Bio Inc - Commences $100 Million Public Offering

THOMSON REUTERS
·
13 Nov 2024

89Bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
13 Nov 2024

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
13 Nov 2024

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)

TIPRANKS
·
11 Nov 2024

89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential

Stock Track
·
09 Nov 2024

89Bio Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

Benzinga
·
08 Nov 2024